Helene Hartvedt Grytli

Association Between Use of β-Blockers and Prostate Cancer–Specific Survival: A Cohort Study of 3561 Prostate Cancer Patients with High-Risk or Metastatic Disease

Helene Hartvedt Grytli, Morten Wang Fagerland, Sophie D. Fosså et al. · European Urology · 2013 · 241 citations

Urology, Oncology, Cancer Epidemiology +8

Use of β‐blockers is associated with prostate cancer‐specific survival in prostate cancer patients on androgen deprivation therapy

Helene Hartvedt Grytli, Morten Wang Fagerland, Sophie D. Fosså et al. · The Prostate · 2012 · 141 citations

PBX3 is a putative biomarker of aggressive prostate cancer

Håkon Ramberg, Helene Hartvedt Grytli, Ståle Nygård et al. · International Journal of Cancer · 2016 · 63 citations · Full text

Prognostic Biomarkers, Urology, Genitourinary Cancer +12

Benefit‐Risk Assessment of Off‐Label Drug Use in Children: The Bravo Framework

Tjitske M. van der Zanden, Miriam G. Mooij, Nienke J. Vet et al. · Clinical Pharmacology & Therapeutics · 2021 · 56 citations · Full text

Substance Use, Benefit‐risk Assessment, Off‐label Drug Use +22

Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy

Peder R. Braadland, Guro F. Giskeødegård, Elise Sandsmark et al. · British Journal of Cancer · 2017 · 43 citations · Full text